In Taiwan, dabrafenib plus trametinib is approved for the treatment of advanced BRAF V600E-positive NSCLC but is not reimbursed by the NHI [1] Crizotinib and entrectinib are approved and reimbursed for the treatment of advanced ROS1-positive NSCLC. Here, BRAF is linked to non-small cell lung carcinoma.